UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders

March 16, 2005

Experts in bioengineering, imaging, molecular genetics, immunology, ethics, hematology/oncology and cellular biology to collaborate on Proposition 71 research

Drawing together experts from fields as diverse as engineering to molecular biology, UCLA officials announced March 16 the formation of the Institute for Stem Cell Biology and Medicine to conduct embryonic and adult stem cell research that may lead to better treatments for HIV, cancer and neurological disorders.

"As one of the world's leading research universities, UCLA has long been engaged in adult and embryonic stem cell research with activities in areas ranging from the AIDS Institute to the Brain Research Institute to the UCLA College," said UCLA Chancellor Albert Carnesale. "The new UCLA Institute for Stem Cell Biology and Medicine will enable us to continue fostering such interdisciplinary collaborations and to build upon the existing body of knowledge for the benefit of people worldwide."

UCLA will provide $20 million over five years to launch the campuswide institute, which will enable teams of researchers to compete for state grants created by the passage of Proposition 71. The money will pay for recruitment for a dozen new faculty positions, salaries and expansion of highly sophisticated laboratory space, infrastructure, and supplies.

Dr. Owen Witte, a renowned scientist whose laboratory research laid the groundwork for development of the targeted leukemia therapy Gleevec, is director of the new institute. He also stressed the interdisciplinary approach necessary to face the challenges related to stem cell research. "Embryonic stem cells have the power to develop into every type of human tissue," said Witte, who also is a professor of microbiology, immunology and molecular genetics, and a Howard Hughes Medical Institute investigator. "If we can learn how they are regulated for growth and development, we can harness this knowledge to study tissue development and regeneration and potentially come up with new ways to fight many life-threatening diseases."

Researchers are hopeful that stem cell research will lead to revolutionary new treatments for Parkinson's, spinal cord injuries, Alzheimer's, cancer and other diseases, and perhaps shed new light on how some diseases develop. However, most scientists agree that human treatments are years or even decades away.

Proposition 71, passed by 59 percent of California voters in November, will provide $3 billion for stem cell research. A state institute is being created in Northern California to allocate funding to stem cell scientists at universities, medical schools and research facilities. Grant applications will be available in May. A 29-member oversight and governing board will oversee the institute and review requests for funding.

"With the launch of this institute, we realize our goal of bringing together scientific, ethical, legal and policy experts from across the UCLA campus to focus on the great promise of stem cell research," said Dr. Gerald S. Levey, vice chancellor for medical sciences and dean of the David Geffen School of Medicine. "As dean, I am committed to advancing the full potential of stem cell research to find novel and more effective therapies to treat many diseases for which present-day therapy is either unsatisfactory or unavailable."

Because the university and medical school at UCLA are located on the same campus, researchers are well positioned to compete for stem cell grant funding, Witte said. UCLA researchers have proven their skill at ushering scientific discoveries from the lab to modern medicine. Several targeted therapies were developed based on UCLA research, including Gleevec and the breast cancer drug Herceptin. Additionally, UCLA scientists played key roles in testing the targeted therapies Avastin and Tarceva.

UCLA also is the only public university in California to boast a sophisticated Good Manufacturing Practice (GMP) suite, a specialized laboratory that is critical for the safe growth and manipulation of stem cell lines. Compliance officers oversee all research in the GMP suite, which must follow stringent federal guidelines for reintroduction of manipulated cells into the human body.

In addition, UCLA's Jonsson Cancer Center features an established clinical trials infrastructure that could be used to test new therapeutics that may develop as a result of the stem cell studies, said Judith C. Gasson, cancer center director, stem cell institute co-director, and a professor of medicine and biological chemistry.

"I see cancer and stem cells as tightly linked," Gasson said. "More and more evidence suggests that cancer is a stem cell disease. Many of our current therapies are not effective because they don't target the cancer stem cells. Our experience with gene medicine and the GMP facilities will make it easier for us to translate our basic stem cell research into human therapies by using facilities and procedures already in place."

The UCLA Institute for Stem Cell Biology and Medicine will focus its embryonic and adult stem cell research in three areas: The Institute for Stem Cell Biology and Medicine is a collaboration of the David Geffen School of Medicine, UCLA's Jonsson Cancer Center, the Henry Samueli School of Engineering and Applied Science, and the UCLA College. Each collaborator brings leading-edge technologies to the table: integrated microfluidics to aid in cell isolation, microarrays and shape encoded particle approaches for gene expression analysis, proteomics using advanced mass spectroscopy, large-scale computational facilities for bioinformatics, and world-class multi modality imaging facilities for analysis of stem cell therapies in laboratory models and, ultimately, in patients enrolled in clinical trials.

"UCLA encourages strong collaborations between faculty in the life sciences and the health sciences," said Patricia O'Brien, executive dean of the UCLA College. "As biomedicine grows increasingly complex, new academic partnerships hold the key to discovery; this institute will create novel opportunities for research that spans many disciplines."

University of California - Los Angeles

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.